Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль позитронно-эмиссионной томографии при различных вариантах злокачественных лимфом: итоги 2020 года
Саржевский В.О., Мухортова О.В. Роль позитронно-эмиссионной томографии при различных вариантах злокачественных лимфом: итоги 2020 года. Современная Онкология. 2021; 23 (1): 192–199.
DOI: 10.26442/18151434.2021.1.200745
DOI: 10.26442/18151434.2021.1.200745
________________________________________________
Sarzhevskiy VO, Mukhortova OV. The role of positron emission tomography in different types of malignant lymphomas: the results of 2020. Journal of Modern Oncology. 2021; 23 (1): 192–199.
DOI: 10.26442/18151434.2021.1.200745
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзоре представлены результаты исследований, опубликованных в 2020 г. и касающихся роли позитронно-эмиссионной томографии (ПЭТ) в диагностике различных вариантов злокачественных лимфом. Авторы постарались выделить современные тенденции развития метода ПЭТ при лимфоме Ходжкина, диффузной В-крупноклеточной лимфоме, фолликулярной лимфоме и множественной миеломе. Отдельно освещена тема использования ПЭТ при иммунотерапии. Также сделан акцент на интерпретации количественных биомаркеров, оцениваемых при ПЭТ. Концепция ПЭТ-адаптированного подхода при лимфоме Ходжкина, прогностическая значимость ПЭТ перед высокодозной химиотерапией с трансплантацией аутологичных гемопоэтических стволовых клеток у пациентов с диффузной В-крупноклеточной лимфомой, прогностическая ценность промежуточной ПЭТ при фолликулярной лимфоме, использование метионина в качестве радиофармпрепарата для диагностики распространения опухоли и оценки минимальной остаточной болезни при множественной миеломе, варианты атипичного ответа опухоли на терапию ингибиторами иммунных контрольных точек, ПЭТ в диагностике иммуноопосредованных нежелательных явлений – темы, актуальные для онкологов, гематологов, радиологов и обсуждаемые в данной статье. В контексте обсуждаемых тем авторы приводят результаты исследований российских пациентов, проходивших ПЭТ-диагностику в ФГБУ «НМИЦ ССХ им. А.Н. Бакулева» Минздрава России.
Ключевые слова: злокачественные лимфомы, позитронно-эмиссионная томография
Ключевые слова: злокачественные лимфомы, позитронно-эмиссионная томография
________________________________________________
The review presents the results of studies published in 2020 concerning the role of positron emission tomography (PET) in the diagnosis of different types of malignant lymphomas. The authors tried to highlight the current trends in the development of the PET method in case of Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The topic concerning the use of PET in immunotherapy is highlighted separately. There was also an emphasis on the interpretation of quantitative imaging biomarkers used in PET. The concept of PET-adapted approach in Hodgkin lymphoma, the predictive significance of PET before high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma, predictive value of intermediate PET in case of follicular lymphoma, the application of methionine as PET tracer to diagnose tumor burden and to measure minimal residual disease in case of multiple myeloma, the variants of atypical tumor response to the immune checkpoint inhibitors therapy, PET in diagnosing immune-mediated adverse events are currently relevant for oncologists, hematologists, radiologists and discussed in this article. In the context of the topics the authors showed the results of PET imaging of Russian patients who had PET examination in the Bakulev National Medical Research Center for Cardiovascular Surgery.
Keywords: malignant lymphomas, positron emission tomography
Полный текст
Список литературы
1. Borchmann P. Positron Emission Tomography guided Omission of Radiotherapy in Early-stage Unfavorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD17 Trial by the GHSG. EHA 25th, p1, abstr S101.
2. Fuchs M, Plütschow A, Kobe C, et al. Prognostic Impact of PET after 2 Cycles of Escalated Beacopp Plus 2 Cycles of ABVD on Progression Free Survival in Early Unfavourable Hodgkin Lymphoma within the Phase 3 GHSG HD17 Trial. ASH 62th, 2020, abstr 2065.
3. Casasnovas O, Racape J, Dechene J, et al. PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa AHL 2011 Phase 3 Study. ASH 62th, 2020, abstr 475.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-sensitive Non-Hodgkin’s Lymphoma. N Engl J Med 1995; 333 (23): 1540–5. DOI: 10.1056/NEJM199512073332305
5. Brown R, Lambertini A, Hofman MS, et al. Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL. ASH 62th, 2020, abstr 3039.
6. Alderuccio JP, Kuker RA, Barreto-Coelho P, et al. Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis. ASH 62th, 2020, abstr 1209.
7. Josting A, Sieniawski M, Glossmann J-P, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16 (8): 1359–65. DOI: 10.1093/annonc/mdi248
8. Cherng H-JJ, Steiner RE, Fayad L,et al. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. ASH 62th, 2020, abstr 3053.
9. Iacoboni PG, Simo M, Villacampa G, et al. Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. ASH 62th, 2020, abstr 1220.
10. Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol 2018; 19 (11): 1530–42. DOI: 10.1016/S1470-2045(18)30618-1
11. Merryman RW, Spilberg G, Mondello P, et al. Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. ASH 62th, 2020, abstr 2936.
12. Mondello P, Strati P, Merryman RW, et al. R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. ASH 62th, 2020, abstr 2041.
13. Morales-Lozano MI, Viering O, Samnick S, et al. 18 F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. Cancers (Basel) 2020; 12 (4): 1042. DOI: 10.3390/cancers12041042
14. Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 2018; 45 (5): 712–9. DOI: 10.1007/s00259-017-3909-8
15. Cavo M, Terpos E, Nanni C, et al. Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18 (4): e206–e217. DOI: 10.1016/S1470-2045(17)30189-4
16. Zamagni E, Nanni C, Gay F, et al. Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial. ASH 62th, 2020, abstr 3326.
17. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 2018; 36 (14): 1428–39. DOI: 10.1200/JCO.2017.76.0793
18. Chen R, Zinzani P, Fanale M, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol 2017; 35 (19): 2125–32. DOI: 10.1200/JCO.2016.72.1316
19. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128 (21). DOI: 10.1182/blood-2016-05-718528
20. Mokrane F-Z, Chen A, Schwartz LH, et al. Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. Radiology 2020; 295 (3): 651-61. DOI: 10.1148/radiol.2020192056
21. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 2017; 23 (8): 1920–8. DOI: 10.1158/1078-0432.CCR-16-1741
2. Fuchs M, Plütschow A, Kobe C, et al. Prognostic Impact of PET after 2 Cycles of Escalated Beacopp Plus 2 Cycles of ABVD on Progression Free Survival in Early Unfavourable Hodgkin Lymphoma within the Phase 3 GHSG HD17 Trial. ASH 62th, 2020, abstr 2065.
3. Casasnovas O, Racape J, Dechene J, et al. PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa AHL 2011 Phase 3 Study. ASH 62th, 2020, abstr 475.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-sensitive Non-Hodgkin’s Lymphoma. N Engl J Med 1995; 333 (23): 1540–5. DOI: 10.1056/NEJM199512073332305
5. Brown R, Lambertini A, Hofman MS, et al. Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL. ASH 62th, 2020, abstr 3039.
6. Alderuccio JP, Kuker RA, Barreto-Coelho P, et al. Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis. ASH 62th, 2020, abstr 1209.
7. Josting A, Sieniawski M, Glossmann J-P, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16 (8): 1359–65. DOI: 10.1093/annonc/mdi248
8. Cherng H-JJ, Steiner RE, Fayad L,et al. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. ASH 62th, 2020, abstr 3053.
9. Iacoboni PG, Simo M, Villacampa G, et al. Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. ASH 62th, 2020, abstr 1220.
10. Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol 2018; 19 (11): 1530–42. DOI: 10.1016/S1470-2045(18)30618-1
11. Merryman RW, Spilberg G, Mondello P, et al. Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. ASH 62th, 2020, abstr 2936.
12. Mondello P, Strati P, Merryman RW, et al. R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. ASH 62th, 2020, abstr 2041.
13. Morales-Lozano MI, Viering O, Samnick S, et al. 18 F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. Cancers (Basel) 2020; 12 (4): 1042. DOI: 10.3390/cancers12041042
14. Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 2018; 45 (5): 712–9. DOI: 10.1007/s00259-017-3909-8
15. Cavo M, Terpos E, Nanni C, et al. Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18 (4): e206–e217. DOI: 10.1016/S1470-2045(17)30189-4
16. Zamagni E, Nanni C, Gay F, et al. Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial. ASH 62th, 2020, abstr 3326.
17. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 2018; 36 (14): 1428–39. DOI: 10.1200/JCO.2017.76.0793
18. Chen R, Zinzani P, Fanale M, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol 2017; 35 (19): 2125–32. DOI: 10.1200/JCO.2016.72.1316
19. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128 (21). DOI: 10.1182/blood-2016-05-718528
20. Mokrane F-Z, Chen A, Schwartz LH, et al. Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. Radiology 2020; 295 (3): 651-61. DOI: 10.1148/radiol.2020192056
21. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 2017; 23 (8): 1920–8. DOI: 10.1158/1078-0432.CCR-16-1741
________________________________________________
1. Borchmann P. Positron Emission Tomography guided Omission of Radiotherapy in Early-stage Unfavorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD17 Trial by the GHSG. EHA 25th, p1, abstr S101.
2. Fuchs M, Plütschow A, Kobe C, et al. Prognostic Impact of PET after 2 Cycles of Escalated Beacopp Plus 2 Cycles of ABVD on Progression Free Survival in Early Unfavourable Hodgkin Lymphoma within the Phase 3 GHSG HD17 Trial. ASH 62th, 2020, abstr 2065.
3. Casasnovas O, Racape J, Dechene J, et al. PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa AHL 2011 Phase 3 Study. ASH 62th, 2020, abstr 475.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-sensitive Non-Hodgkin’s Lymphoma. N Engl J Med 1995; 333 (23): 1540–5. DOI: 10.1056/NEJM199512073332305
5. Brown R, Lambertini A, Hofman MS, et al. Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL. ASH 62th, 2020, abstr 3039.
6. Alderuccio JP, Kuker RA, Barreto-Coelho P, et al. Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis. ASH 62th, 2020, abstr 1209.
7. Josting A, Sieniawski M, Glossmann J-P, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16 (8): 1359–65. DOI: 10.1093/annonc/mdi248
8. Cherng H-JJ, Steiner RE, Fayad L,et al. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. ASH 62th, 2020, abstr 3053.
9. Iacoboni PG, Simo M, Villacampa G, et al. Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. ASH 62th, 2020, abstr 1220.
10. Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol 2018; 19 (11): 1530–42. DOI: 10.1016/S1470-2045(18)30618-1
11. Merryman RW, Spilberg G, Mondello P, et al. Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. ASH 62th, 2020, abstr 2936.
12. Mondello P, Strati P, Merryman RW, et al. R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. ASH 62th, 2020, abstr 2041.
13. Morales-Lozano MI, Viering O, Samnick S, et al. 18 F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. Cancers (Basel) 2020; 12 (4): 1042. DOI: 10.3390/cancers12041042
14. Nanni C, Versari A, Chauvie S, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging 2018; 45 (5): 712–9. DOI: 10.1007/s00259-017-3909-8
15. Cavo M, Terpos E, Nanni C, et al. Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18 (4): e206–e217. DOI: 10.1016/S1470-2045(17)30189-4
16. Zamagni E, Nanni C, Gay F, et al. Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial. ASH 62th, 2020, abstr 3326.
17. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 2018; 36 (14): 1428–39. DOI: 10.1200/JCO.2017.76.0793
18. Chen R, Zinzani P, Fanale M, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol 2017; 35 (19): 2125–32. DOI: 10.1200/JCO.2016.72.1316
19. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128 (21). DOI: 10.1182/blood-2016-05-718528
20. Mokrane F-Z, Chen A, Schwartz LH, et al. Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. Radiology 2020; 295 (3): 651-61. DOI: 10.1148/radiol.2020192056
21. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 2017; 23 (8): 1920–8. DOI: 10.1158/1078-0432.CCR-16-1741
Авторы
В.О. Саржевский*1, О.В. Мухортова2
1 ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России, Москва, Россия
*vladsar100@gmail.com
1 ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России, Москва, Россия
*vladsar100@gmail.com
________________________________________________
Vladislav O. Sarzhevskiy*1, Olga V. Mukhortova2
1 Pirogov National Medical and Surgical Center, Moscow, Russia;
2 Bakulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russia
*vladsar100@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.